1. Home
  2. VITL vs KMDA Comparison

VITL vs KMDA Comparison

Compare VITL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$12.72

Market Cap

550.6M

ML Signal

HOLD

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$8.22

Market Cap

488.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
KMDA
Founded
2007
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
550.6M
488.6M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
VITL
KMDA
Price
$12.72
$8.22
Analyst Decision
Buy
Strong Buy
Analyst Count
11
2
Target Price
$32.00
$14.00
AVG Volume (30 Days)
2.4M
43.3K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
3.02%
EPS Growth
22.03
N/A
EPS
1.44
N/A
Revenue
$759,444,000.00
N/A
Revenue This Year
$19.72
$13.94
Revenue Next Year
$17.02
$9.84
P/E Ratio
$8.76
$24.59
Revenue Growth
25.26
N/A
52 Week Low
$12.12
$6.35
52 Week High
$53.13
$9.35

Technical Indicators

Market Signals
Indicator
VITL
KMDA
Relative Strength Index (RSI) 36.48 44.41
Support Level $12.35 $7.96
Resistance Level $14.57 $8.50
Average True Range (ATR) 0.78 0.18
MACD 0.35 -0.01
Stochastic Oscillator 33.15 18.37

Price Performance

Historical Comparison
VITL
KMDA

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: